← The Wire
VNDANasdaq
Vanda Pharmaceuticals Inc.
Pharmaceutical Preparations · DE · CIK 1347178
Develops and commercializes innovative therapies for unmet medical needs using genetics and genomics
red 8-K · 90d
$353M
Market cap
$6.14
Last close
+2.2%
1D
+2.3%
5D
874K
Volume
Price · last 39 sessions-18.8%
May 4L $5.73 · H $7.56Jun 29
408
Total filings
Jun 5, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 5, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 6, 2026DEFA14ADEFA14AApr 23, 2026DEF 14ADEF 14AApr 23, 20268-KExecutive ChangeApr 22, 20268-KExecutive ChangeApr 2, 20268-KReg FD DisclosureMar 10, 20268-KCompany UpdateFeb 23, 20268-KExecutive ChangeFeb 19, 202610-K10-KFeb 12, 20268-KResults of OperationsFeb 11, 20268-KCompany UpdateJan 8, 20268-KCompany UpdateDec 31, 20258-KCompany UpdateDec 4, 20258-KCompany UpdateNov 28, 202510-Q10-QOct 30, 20258-KResults of OperationsOct 29, 20258-KCompany UpdateOct 1, 202510-Q10-QJul 31, 20258-KResults of OperationsJul 31, 20258-KShareholder VoteJun 5, 2025DEFA14ADEFA14AMay 27, 202510-Q10-QMay 8, 20258-KResults of OperationsMay 7, 2025DEFA14ADEFA14AApr 25, 2025DEF 14ADEF 14AApr 25, 20258-KReg FD DisclosureMar 17, 20258-KExecutive ChangeFeb 20, 202510-K10-KFeb 14, 20258-KResults of OperationsFeb 13, 20258-KReg FD DisclosureJan 27, 202510-Q10-QNov 7, 20248-KResults of OperationsNov 6, 20248-KCompany UpdateOct 15, 20248-KBylaw AmendmentOct 3, 20248-KCompany UpdateSep 19, 20248-KMaterial Agreement · Security-Holder RightsAug 8, 202410-Q10-QAug 1, 20248-KResults of OperationsJul 31, 20248-KCompany UpdateJun 20, 20248-KCompany UpdateJun 13, 20248-KReg FD DisclosureJun 6, 20248-KCompany UpdateMay 24, 20248-K/AShareholder VoteMay 24, 20248-KShareholder VoteMay 20, 2024DEFA14ADEFA14AMay 13, 2024DEFA14ADEFA14AMay 9, 202410-Q10-QMay 9, 20248-KResults of OperationsMay 8, 20248-KCompany UpdateMay 7, 20248-KMaterial Agreement · Security-Holder RightsMay 3, 2024DEF 14APROXY STATEMENTApr 29, 20248-KMaterial Agreement · Security-Holder RightsApr 17, 20248-KCompany UpdateApr 3, 20248-KCompany UpdateMar 7, 20248-KExecutive ChangeFeb 21, 20248-K/ACompany UpdateFeb 16, 202410-K10-KFeb 8, 20248-KResults of OperationsFeb 7, 20248-KCompany UpdateFeb 5, 20248-KBylaw AmendmentDec 15, 20238-KMaterial Agreement · Acquisition / DispositionDec 7, 202310-Q10-QNov 9, 20238-KResults of OperationsNov 8, 20238-KCompany UpdateAug 21, 202310-Q10-QJul 28, 20238-KResults of OperationsJul 27, 20238-KShareholder VoteJun 8, 20238-KCompany UpdateMay 11, 202310-Q10-QMay 3, 20238-KResults of OperationsMay 3, 2023DEFA14ADEFA14AApr 24, 2023DEF 14ADEF 14AApr 24, 20238-KExecutive ChangeMar 17, 20238-KReg FD DisclosureMar 13, 20238-KExecutive ChangeFeb 17, 2023SC 13GSEC SCHEDULE 13GFeb 10, 202310-K10-KFeb 9, 20238-KResults of OperationsFeb 8, 2023
Insider Activity
In the 90 days to Mar 2, 2026: 6 sold $2.8M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Polymeropoulos Mihael HristosPresident and CEO | Sell | 156,235 | $8.17 | $1.3M |
| Mar 2, 2026 | Moran Kevin PatrickSVP, CFO & Treasurer | Sell | 42,442 | $8.27 | $351K |
| Mar 2, 2026 | Williams TimothySVP & General Counsel | Sell | 42,434 | $8.27 | $351K |
| Mar 2, 2026 | Birznieks GuntherSVP, Business Development | Sell | 42,431 | $8.27 | $351K |
| Mar 2, 2026 | Wijkstrom JoakimSVP, Chief Marketing Officer | Sell | 30,800 | $8.27 | $255K |
| Feb 23, 2026 | Honore TageDirector | Sell | 30,000 | $8.03 | $241K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance